Abstract
Objective: We aimed to assess the incidence, management, and visual outcome of acute endophthalmitis in patients following intravitreal bevacizumab injection in a tertiary care setup. It was a prospective and single-center database study.Patients and methods: Patients receiving intravitreal bevacizumab injections for various retinal vascular diseases from January 2019 to September 2020. The study was carried out at the Institute of Ophthalmology, Mayo Hospital, Lahore over a period of 21 months. Preformed bevacizumab injections were administered intravitreally on patients of various retinal vascular diseases under strict aseptic measures and by following the standard guidelines. The patients were put on follow-ups for a duration of four weeks to see any signs of acute endophthalmitis.Results: A total of 3051 injections were administered in 1104 eyes of 743 patients during the above-mentioned study period. The incidence of endophthalmitis was found to be 0.0328% (1/3051). The patient, who developed endophthalmitis, was treated with topical and intravitreal antibiotics followed by vitrectomy that resulted in clinically significant improvement in vision.Conclusion: Incidence of acute endophthalmitis following intravitreal bevacizumab injection was low and could be prevented by taking strict aseptic measures during administration.
Highlights
Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor-A (VEGF-A)
The patient, who developed endophthalmitis, was treated with topical and intravitreal antibiotics followed by vitrectomy that resulted in clinically significant improvement in vision
It is primarily an anti-cancerous drug approved to be used systematically in a variety of cancers like colorectal, renal, etc. It works by blocking the abnormal proliferation of blood vessels by inhibiting VEGF-A, so it is being employed in various ocular vascular proliferative disorders, preventing and slowing down visual loss caused by leakage from the newly formed vessels
Summary
Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor-A (VEGF-A). It is primarily an anti-cancerous drug approved to be used systematically in a variety of cancers like colorectal, renal, etc It works by blocking the abnormal proliferation of blood vessels by inhibiting VEGF-A, so it is being employed in various ocular vascular proliferative disorders, preventing and slowing down visual loss caused by leakage from the newly formed vessels. It is indicated in retinal vascular diseases like exudative age-related macular degeneration (ARMD), or macular edema due to diabetic retinopathy and retinal vein occlusion. None of these adverse events has a rate exceeding 0.27% [1]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
